Synopsis:
Ajanta Pharma gained 3% after Q2FY26 revenue rose 14% YoY to ₹1,353.73 cr and profit 20% to ₹260.19 cr. It has also announced a ₹28/share (1,400%) interim dividend.
The shares of the Pharma stock company specializing in developing, manufacturing, and marketing pharmaceutical products across various therapeutic areas, jumped upto 3 percent following their Q2 results and dividend declaration.
With a market capitalization of 31,626.20 Crores on Monday, the shares of Ajanta Pharma Ltd jumped upto 3.07 percent, reaching a high of Rs. 2540.00 compared to its previous close of Rs. 2464.15.
What Happened
Ajanta Pharma Ltd, engaged in developing, manufacturing, and marketing pharmaceutical products across various therapeutic areas, has announced its Q2 results as follows:
Its Revenue from operations rose by 14 percent YoY from Rs. 1,186.64 Crores in Q2FY25 to Rs. 1,353.73 Crores in Q2FY26, and it rose by 4 percent QoQ from Rs. 1,302.65 Crores in Q1FY26 to Rs. 1,353.73 Crores in Q2FY26.
Its Net Profit YoY rose by 20 percent from Rs. 216.48 Crores in Q2FY25 to Rs. 260.19 Crores in Q2FY26, and it rose by 2 percent QoQ from Rs. 255.34 Crores in Q1FY26 to Rs. 260.19 Crores in Q2FY26. The earnings per share (EPS) for the quarterly period stood at Rs. 20.83, compared to Rs. 20.44 in the previous quarter.
Along with it, the Board of Directors has approved the 1st interim dividend of Rs. 28 per share for the face value of Rs. 2 per share (1,400% Dividend), amounting to Rs. 350 cr.
Furthermore, as per IQVIA MAT September 2025, Ajanta Pharma’s India branded generics business outperformed the Indian Pharmaceutical Market (IPM) by 32%. This strong performance was primarily driven by a 115% higher growth in volumes and a 39% higher contribution from new product launches compared to the IPM, highlighting the company’s robust product portfolio and successful market execution.
Company Overview & Others
Ajanta Pharma is a specialty pharmaceutical formulation company focused on the branded generics business across India, Asia, and Africa, with a strong ground presence in over 30 countries. Many of its products are first-to-market and hold leadership positions in their sub-therapeutic segments.
The company also operates in the U.S. generic market and the institutional business in Africa. Its state-of-the-art R&D centre is based in Mumbai, supported by seven world-class manufacturing facilities in India. Over the past three financial years, Ajanta Pharma has delivered a healthy revenue CAGR of 11% and an even stronger PAT CAGR of 25%, reflecting its consistent growth and operational excellence.
It also demonstrates strong financial performance with a ROCE of 32.4% and ROE of 24.9%, indicating efficient use of capital and shareholder funds. It maintains a very low debt-to-equity ratio of 0.01, reflecting minimal leverage. Additionally, the company has been consistent in rewarding shareholders, maintaining a healthy dividend payout of 44%.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
